Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

<p>Abstract</p> <p>Background</p> <p>Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the mammalian target of rapamycin (mTOR)-inhibitor RAD001...

Descripció completa

Dades bibliogràfiques

Autors principals:	Waaga-Gasser Ana, Tsaur Igor, Juengel Eva, Makarević Jasmina, Seibel Jens-Michael, Hudak Lukasz, Wedel Steffen, Haferkamp Axel, Blaheta Roman A
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2011-08-01
Col·lecció:	BMC Cancer
Accés en línia:	http://www.biomedcentral.com/1471-2407/11/375
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!